Breaking Barriers

Personalized medicine enhances treatment effectiveness while reducing side effects and costs by eliminating ineffective plans. It benefits patients through quicker access to effective treatments, saves insurance companies from costly medications, and allows pharmaceutical firms to streamline R&D processes, potentially accelerated by AI technologies. However, a key limitation is the access to vast amounts of patient data needed for clinical trials. Challenges such as difficult data access and unclear legal frameworks hinder this process, especially when integrating AI. Sourcing thousands of data records for trials can be resource-intensive and potentially lead to significant financial burdens. Leveraging modern technology could reduce these costs and expedite time to market.

How can data anonymization facilitate effective and efficient use of patient data while minimizing limitations that come along with anonymization?

The data anonymization process eliminates patient identifiers and lifts specific usage restrictions from the data. The latest anonymization technology also ensures that the anonymized data maintains the statistical integrity of the original dataset, thereby protecting privacy without sacrificing data utility.

By adopting anonymization, the pharmaceutical industry can collaborate with hospitals that possess an abundance of untapped data. The anonymized data can not only be used for internal research and drug development but can also be sold to third parties, introducing new revenue opportunities.

Our team of experts is ready to help you unlock the power of healthcare data and integrate our anonymization technology in your application. The anonymization solution is independent of the current messaging or data standards you are utilizing and among others works with DICOM, FHIR and HL7 data.